4 / 9
allied
academies
Page 41
Notes:
Journal of Psychology and Cognition | Volume 4
May 13-14, 2019 | Prague, Czech Republic
Addiction Research and Therapy
2
nd
International Conference on
J Psychol Cognition, Volume 4
Genetic Addiction Risk Score (GARS®) with precision Pro-Dopamine Regulation matched to polymorphic risk
alleles to combat Reward Deficiency Syndrome (RDS) including Substance Use Disorder (SUD) globally
Kenneth Blum
1,2
, Marjorie C Gondré Lewis
2,3
, David Baron
1,2
, Lisa Lott
2
, Jessica Ponce-Rodriquez
2
, Mark Moran
2
,
Lyle Fried
4
and
Rajendra D Badgaiyan
2,5
1
Western University, USA,
2
Geneus Health, USA,
3
Howard University, USA,
4
Translational Treatment Center, USA,
5
Ichan School of
Medicine, USA
R
esearch into the neurogenetic basis of addiction identified
and characterized by Reward Deficiency Syndrome (RDS)
includes all drug and non-drug addictive, obsessive and
compulsive behaviours. This keynote presents a new model
for the prevention and treatment of RDS behaviours based
on objective biologic evidence. Currently, research directed
toward improving treatment for highly drug-dependent
patients in underserved populations is the basis of an NIH
grant awarded to Kenneth Blum and Marjorie Gondré-Lewis.
The grant explores utilization of the Genetic Addiction Risk
Score (GARS) and the neuronutrient pro-dopamine regulator
KB220. The development of GARS followed seminal research
in 1990, whereby, Blum’s group identified the first genetic
association with severe alcoholism. The non-invasive GARS
test identifies and measures the total number of risk alleles
of genes and catabolic enzymes affecting an individual's
neurochemical hypodopaminergic function and has been
associated in hundreds of studies with RDS behaviours. In
an unpublished study, the GARS predicted drug and alcohol
severity predisposition as measured by the Addiction Severity
Index (ASI) [≤ 4 alleles for Drug & ≤ 7 alleles for Alcohol].
Genotyping data on approximately 1000 subjects [addicted,
chronic pain, opioid maintained and non-addicted] will be
presented. “Precision Behavioural Management” (PBM®)
uses the GARS to customize KB220PAM formulations to
deliver putative dopamine homeostasis based on developed
algorithms matched to polymorphic results. Presented
evidence derived from animal and human studies using
BOLD neuroimaging and behavioural methodologies, support
homeostatic activation of brain dopamine in the reward
circuitry by KB220PAM, as well as anti-substance seeking and
modificationofRDSbehaviours.RDSencompassesbehaviours
like PTSD, ADHD, over-eating, shopping, hoarding and related
RDS cognitive insults. Combating the drug crisis requires PBM
across ethnic groups, to bring dopamine homeostasis to
those born with RDS predisposition. It is the goal through this
novel model that by using PBM the addiction field will have a
synergistic tool along with MAT or even alone, to overcome
dopamine dysregulation either surfeit (adolescents) or
deficit (adults) by the induction of “dopamine homeostasis.”
e
:
drd2gene@gmail.com